WAT

Waters Corporation
NYSEHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$90.45B
P/E Ratio
192.57
EPS
$2.39
Beta
1.15
52W High
$483.33
52W Low
$282.77
50-Day MA
$440.21
200-Day MA
$373.20
Dividend Yield
—
Profit Margin
1.76%
Forward P/E
27.47
PEG Ratio
1.84

About Waters Corporation

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$5.61B
Gross Profit (TTM)$3.11B
EBITDA$1.76B
Operating Margin16.00%
Return on Equity1.12%
Return on Assets3.87%
Revenue/Share (TTM)$66.00
Book Value$155.60
Price-to-Book5.92
Price-to-Sales (TTM)16.12
EV/Revenue8.94
EV/EBITDA43.54
Quarterly Earnings Growth (YoY)-67.00%
Quarterly Revenue Growth (YoY)120.90%
Shares Outstanding$98.29M
Float$98.10M
% Insiders0.58%
% Institutions103.74%

Historical Volatility

HV 10-Day
36.90%
HV 20-Day
34.00%
HV 30-Day
31.18%
HV 60-Day
27.02%
HV Rank
57.9%

Volatility is currently expanding

Analyst Ratings

Consensus ($503.29 target)
3
Strong Buy
15
Buy
4
Hold
1
Strong Sell

Latest News

Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma

BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity1 in identifying chronic lymphocytic leukemia (CLL), one of the most common types of NHL All-in-one solution reduces 95% of manual steps,2 delivering workflow efficiency, fast turnaround times, and a reduction in errors MILFORD, Mass., Nov. 10, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

PRNewsWire11/10/2026Neutral
Madison Mid Cap Fund Q3 2026 Portfolio Activity

The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvity, and Waters Corporation. The bottom five detractors for the quarter were MKS, Floor & Decor Holdings, Carlisle Companies, Moelis and Co., and Glacier Bancorp.

Seeking Alpha11/6/2026Neutral
Waters Q3 Earnings Call Highlights

Waters NYSE: WAT reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share of $4.10, as the company cited double-digit organic growth, improving performance in acquired businesses and cost actions that supported profitability.

MarketBeat11/4/2026Positive
Waters (WAT) Beats Q3 Earnings and Revenue Estimates

Waters (WAT) came out with quarterly earnings of $4.1 per share, beating the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $3.4 per share a year ago.

Zacks Investment Research11/3/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WAT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/16/2026